Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
NovaGo Therapeutics General Information
First patient with acute spinal cord injury was enrolled and dosed in Phase 1b clinical trial as of January 7, 2025. The company's therapeutic antibody candidates have shown to enhance nerve repair and functional recovery in preclinical models.
Contact Information
Primary Industry
Biotech
Corporate Office
Schlieren,
Switzerland
Switzerland
Drug Pipeline
NG004
Phase 1Key Partnerships
Neurimmune
NovaGo Therapeutics Funding
No funding data available
To view NovaGo Therapeutics's complete valuation and funding history, request access »